Rajana, Naveen Chary, Padakanti Sandeep Pooja, Yeruva Sri Bhavana, Valamla Singh, Hoshiyar Guru, Santosh Kumar Singh, Shashi Bala Mehra, Neelesh Kumar
Published in
Drug delivery and translational research
Breast cancer is reported as one of the most prevalent non-cutaneous malignancies in women. Venetoclax (VEN) is an approved BCl-2 inhibitor for the treatment of chronic myeloid leukemia with very limited oral bioavailability and exhibits an enormous impact on breast cancer. In the current investigation, venetoclax-loaded self-nanoemulsifying drug d...
Zhao, Lei Yang, Jinjun Chen, Mengran Xiang, Xinrong Ma, Hongbing Niu, Ting Gong, Yuping Chen, Xinchuan Liu, Jiazhuo Wu, Yu
...
Published in
Annals of hematology
Venetoclax (VEN), a BCL-2 inhibitor, has transformed treatment strategies for elderly and unfit acute myeloid leukemia (AML) patients by significantly improving response rates and survival. However, the predictive factors for VEN efficacy differ from traditional chemotherapy. The clinical relevance of the FAB (French-American-British) monocytic sub...
Hu, Xiaoyi Ediriwickrema, Asiri Saleem, Atif Tan, Brent Pemmaraju, Naveen Mannis, Gabriel N
Published in
Leukemia research
Chen, Hongxia Wang, Ning Li, Yin Xie, Xiaohong Yang, Yi
Published in
Frontiers in Oncology
Atypical Chronic Myeloid Leukemia (aCML), a myeloproliferative neoplasm with poor prognosis, was reclassified as aCML by the ICC classification, and as MDS/MPN with neutrophilia by the WHO 2022 classification. Due to the heterogeneity of its clinical features and the lack of unique biomarkers, as well as limited treatment options, aCML currently la...
Diekmann, Benno Timmerman, Marjolijn Hempenius, Liesbeth van Roon, Eric Franken, Bas Hoogendoorn, Mels
Published in
Journal of geriatric oncology
With the introduction of targeted chemotherapy drugs, a new age of treatment for acute myeloid leukemia (AML) has begun. The promotion of the azacitidine+venetoclax combination regimen to first line of treatment in patients deemed ineligible for intensive chemotherapy marks the first of many novel combination regimens becoming part of national trea...
Malarikova, Diana Jorda, Radek Kupcova, Kristyna Senavova, Jana Dolnikova, Alexandra Pokorna, Eva Kazantsev, Dmitry Nozickova, Kristina Sovilj, Dana Bellanger, Celine
...
Background: Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhibitor.Methods: A panel of nine MCL cell lines were used fo...
Durand, Romane Bellanger, Céline Kervoëlen, Charlotte Tessoulin, Benoit Dousset, Christelle Menoret, Emmanuelle Asnagli, Hélène Parker, Andrew Beer, Philip Pellat-Deceunynck, Catherine
...
Innovative therapeutic strategies have emerged over the past decade to improve outcomes for most lymphoma patients. Nevertheless, the aggressive presentation seen in high-risk mantle cell lymphoma (MCL) patients remains an unmet medical need. The highly proliferative cells that characterize these tumors depend on nucleotide synthesis to ensure high...
Vaidya, Poorva Wang, Huan-You Don, Michelle Hinds, Brian Mangan, James
Near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare hematologic malignancy, for which second line therapeutic options are limited. T-cell leukemias are also rarely associated with leukemia cutis, which is more often seen in leukemias of myeloid origin. We present the case of an adult male diagnosed with near ETP-ALL, with I...
Hurrish, Katie H Su, Yongwei Patel, Shraddha Ramage, Cassandra L Zhao, Jianlei Temby, Brianna R Carter, Jenna L Edwards, Holly Buck, Steven A Wiley, Sandra E
...
Published in
Biochemical pharmacology
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these therapies, most patients succumb to the disease due to relapse and/or drug resistance...
Ling, Qing Zhou, Yutong Qian, Yu Qian, Jiejing Zhang, Yi Wang, Jinghan Zhu, Yanan Zhou, Yile Wei, Juying Yang, Chunmei
...
Published in
Biomarker research
KMT2A-rearranged acute myeloid leukemia (KMT2Ar-AML) is an aggressive subtype of AML with poor response and prognosis. KMT2Ar-AML has been demonstrated to be sensitive to BCL2 inhibitor venetoclax (VEN), but these patients are unable to benefit from current VEN-based regimen (VEN plus azacitidine or low dose-cytarabine), so a novel and KMT2A rearra...
